Marker Therapeutics is trading at $1.01, up 6.17%; broader biotech strength provides context, but no company-specific catalyst was identified for October 28.
- Its latest identified announcement was an FDA grant disclosed October 19, before this move.
- XBI rose 2.18% during the regular session.
- Intraday volume or activity data were not available in the provided price context.